{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
M020
(2011)
Source URL:
First approved in 2011
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Chlorhexidine FLUSH by Stratford Care Usa, Inc.
(2011)
Source URL:
First approved in 2011
Source:
Chlorhexidine FLUSH by Stratford Care Usa, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02117869: Phase 4 Interventional Completed Pharmacokinetics
(2014)
Source URL:
First approved in 2011
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
D-COL Nasal Inner Rim Cleanser by D-COL Inc
(2018)
Source URL:
First approved in 2011
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
SHEZA GUSL FIRMING MASK PACK by PISATAP
(2013)
Source URL:
First approved in 2011
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 356
(2011)
Source URL:
First approved in 2011
Source:
21 CFR 356
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2018)
Source URL:
First approved in 2011
Source:
Proactiv MD Ultra-Hydrating Moisturizer by Alchemee, LLC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03117322: Phase 4 Interventional Completed Cerebral Palsy
(2017)
Source URL:
First approved in 2011
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 355
(2011)
Source URL:
First approved in 2011
Source:
21 CFR 355
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Ginseng Khan by Korea Genetic Pharm Co., Ltd
Source URL:
First approved in 2011
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE